Ambiq - [AMBQ] a hidden smallcap enabling Edge AI: investment thesis ahead of today earnings release.

The problem nobody is talking about

The dirty secret of the robotics industry — from Tesla's Optimus to the humblest warehouse drone — is runtime. Most humanoids still run only 2 to 4 hours on a charge. That falls far short of the 8 to 12 hours that define real-world shifts.

The industry is crashing into a hard reality: there is no Moore's Law for batteries. Computing power doubles every 18 months. Battery energy density improves a meager 3% to 5% per year. In the cloud, you throw infinite megawatts at a compute problem. At the edge, you are fighting a localized war for every single milliwatt.

Instead of praying for a magically better battery, we need a chip that consumes one-fifth of the power. This is where Ambiq comes in.

The technology: SPOT

Standard chips operate at 1.2V or higher — think of it as building a 10-foot wide sidewalk for electrons. Safe, reliable, but it costs a fortune in energy.

Ambiq operates in the sub-threshold region at less than 0.5V — their proprietary SPOT (Sub-threshold Power Optimized Technology). Instead of a wide sidewalk, Ambiq forces electrons to walk a single tightrope.

The tightrope uses almost no energy. But it is incredibly dangerous. At such low power levels, random atomic vibration (thermal noise) is strong enough to knock an electron off the wire entirely — the signal is lost and the device crashes.

This is Ambiq's moat: not the idea of the tightrope, but the 15 years of scars they accumulated figuring out how to walk it without falling. Intel, ARM, and STMicro can design a sub-threshold chip in a lab. When they try to mass-produce it, manufacturing variance — slight temperature differences, silicon quality across a wafer — knocks them right off. Ambiq has quietly shipped 280 million MCUs while solving exactly this problem.

Where Ambiq is today

For its first decade, Ambiq was essentially a glorified R&D lab. When they finally commercialized (2018–2023), they sold to whoever would write a check — $1–$2 chips to Xiaomi and Huawei for $30 fitness trackers. Empty calorie revenue with margins that barely kept the lights on.

July 2025: Ambiq IPO'd, raising ~$110M. Management made a clean strategic break — walking away from the low-margin Chinese commodity business and moving upmarket:

• Before: $1–$2 chips to Xiaomi for step-counters
• After: $4+ chips (Apollo 4 & 5) to Garmin, Whoop, and Google

Top-line revenue is taking a breather as they exit the commodity business. But gross margins have expanded from the low 30s to 44%–45% today. We care far more about the quality of revenue than the quantity.

Where Ambiq is going: the asymmetry

If Ambiq's ultimate future is just "selling more chips to Garmin," we are not interested. That is not a wealth-generating anomaly.

The real thesis is Atomiq — a new 12nm chip with a dedicated Neural Processing Unit (NPU) purpose-built to run neural networks locally, at ultra-low power. Revenue ramp targeted for 2028. This transforms Ambiq from a "smartwatch company" into a true Edge AI platform, unlocking:

• Security cameras doing local facial ID without streaming to the cloud
• Industrial sensors predicting machine breakdowns weeks in advance via vibration analysis
• Robots that can navigate environments without dying in two hours

There is also a broader platform shift at play. The market is quietly converging on smart glasses as the post-smartphone computing platform. Zuckerberg has bet Meta's future on it. The Ray-Ban Meta glasses — screenless but proving consumers will wear face-computers if they are stylish — validate the direction. AMBQ is effectively a long call option on the post-smartphone era.

Un-modeled upside: licensing. Ambiq plans to license SPOT technology to semiconductor peers, with initial engagements expected by 2027. Wall Street analysts explicitly exclude this from their models. Any positive development here — at near 100% margins — translates directly into stock returns. We are watching their LinkedIn job postings for design team hiring as the early signal.

Valuation: brutal honesty

At ~$30–$35/share, AMBQ trades at 7x–8.5x forward revenue and 5.5x–6.5x 2027 revenue.

For context:

• Nordic Semiconductor (20% growth, 50%+ gross margins, FCF positive): 3x 2027 sales
• Silicon Labs (15%+ growth, 60%+ gross margins): 6x 2027 sales
• AMBQ (losing money, 2–3 years from breakeven): 6.5x 2027 sales

We are undeniably paying an AI hype tax. The next two years will likely be boring on the income statement — linear revenue growth toward ~$100M, margins improving to 50%+. This stock might be dead money for 18 months. Management will pour every dollar of gross profit back into Atomiq R&D.

The balance sheet is our primary risk metric: ~$150M cash, zero debt, burning ~$2.5M/month. That gives them runway to the 2028 Atomiq launch on a spreadsheet. In reality, silicon is hard. A six-month delay on Atomiq due to a foundry yield issue and we are staring down a dilutive capital raise.

Our game plan

If you buy today, you must accept the market is in "show me" mode and Ambiq literally cannot show its full hand until 2028.

• Macro correction to ~$20? That is a gift — compresses to ~4x 2027 sales and finally gives a true margin of safety. We would add aggressively.
• Believers comfortable being early: 0.5%–1.0% starter position, scale up on dips while the thesis stays intact. No meaningful returns expected until 2027–2028.
• Conservative investors: Keep on watchlist. Let them execute the Apollo 5 ramp for 2–3 more quarters. You pay a higher price later but buy with significantly less execution risk.

Yesterday we added to our position ahead of today Q4 earnings print. Not because we expect a blowout quarter — the near-term financials will look ugly by design. We added because the thesis is intact and we want more exposure before any positive Atomiq development gets priced in by the street. Oh... and last but not least — we did not have a round number of shares to sell a clean options lot, so we fixed that too 😂😂😂

Happy to share more details on our position sizing and other names we are watching in the comments.

Not financial advice. We own AMBQ in our portfolio.